Search

everythinglearnresearchcommunity

for

Search:↓

Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Three compounds from Dadap leaves may help treat hair loss.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

JAK inhibition may help manage autoimmune conditions in Down syndrome.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Baricitinib is effective and safe for treating severe alopecia areata.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Regenerative therapies show promise for treating vitiligo and alopecia areata.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.